Division of Surgical Oncology, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
Alabama College of Osteopathic Medicine, Dothan, Alabama.
J Surg Res. 2020 Nov;255:469-474. doi: 10.1016/j.jss.2020.05.074. Epub 2020 Jul 1.
Previously, fine-needle aspiration biopsy was recommended for any thyroid nodule >1.0 cm in size. In 2015, the American Thyroid Association (ATA) introduced a pattern-based approach for biopsy recommendations based on size and ultrasound (US) characteristics. In 2016, the American College of Radiology (ACR) published the Thyroid Imaging Reporting and Data System, using a point-based system that assesses risk of US characteristics.
This study aims to compare recommendations for thyroid nodule biopsy between the ATA and ACR systems and identify outcomes of nodules with discordant recommendations (DRs). US characteristics, fine-needle aspiration biopsy, and surgical pathology results were evaluated for all patients with >1.0 cm thyroid nodules treated at a single tertiary-care institution from 2010 to 2018.
Inclusion criteria were met by 1100 nodules from 687 patients; 42.8% (n = 471) had DR between the ATA and ACR guidelines. All (100%) DR nodules were not recommended for biopsy by ACR, though 53% were recommended to have follow-up. A majority (79%) of DR nodules were recommended for biopsy by ATA, with the remaining 21% recommended for follow-up. Among surgically excised DR nodules (n = 292), 10.3% (n = 30) nodules were found to be malignant, with the vast majority (90.3%) being well-differentiated carcinoma. Among malignant nodules, the ACR would not have recommended biopsy or follow-up for 26.7% (n = 8).
The ACR classification system is more restrictive compared with the ATA system for recommending thyroid nodule biopsy. This discrepancy could result in confusion for clinicians and delay in diagnosis or therapy for patients with thyroid cancer.
此前,对于任何大于 1.0 厘米的甲状腺结节都推荐进行细针穿刺活检。2015 年,美国甲状腺协会(ATA)基于大小和超声(US)特征引入了一种基于模式的活检推荐方法。2016 年,美国放射学会(ACR)发布了甲状腺影像报告和数据系统,采用基于点的系统来评估 US 特征的风险。
本研究旨在比较 ATA 和 ACR 系统对甲状腺结节活检的推荐,并确定存在不一致推荐(DR)的结节的结局。对 2010 年至 2018 年在一家三级保健机构治疗的所有大于 1.0 厘米甲状腺结节患者的 US 特征、细针穿刺活检和手术病理结果进行了评估。
纳入标准满足了 687 例患者的 1100 个结节;42.8%(n=471)的结节在 ATA 和 ACR 指南之间存在 DR。所有(100%)DR 结节均不被 ACR 推荐进行活检,尽管 53%的结节被推荐进行随访。ATA 推荐对大多数(79%)DR 结节进行活检,其余 21%的结节推荐进行随访。在手术切除的 DR 结节(n=292)中,有 10.3%(n=30)的结节为恶性,其中绝大多数(90.3%)为分化良好的癌。在恶性结节中,ACR 不会推荐对 26.7%(n=8)的结节进行活检或随访。
与 ATA 系统相比,ACR 分类系统对推荐甲状腺结节活检更具限制性。这种差异可能导致临床医生感到困惑,并导致甲状腺癌患者的诊断或治疗延迟。